This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV)and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non- cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and / or cannabichromene (CBC).More particularly still the composition is absent or substantially absent of other cannabinoids, including in particular tetrahydrocannabinol (THC) and tetrahydrocannabivarin (THCV), which would normally be present in significant amounts in cannabis chemotypes bred to contain a significant amount of CBDV and / or CBD.

A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (cbdv) and cannabidiol (cbd)

The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Use of cannabinoids in the treatment of epilepsy

The present invention discloses a cannabis based emulsion formulation for use in various medical conditions and optionally with various pharmaceutical or nutraceutical compositions, wherein the oily fraction used contains about 50% cannabinoids. The present invention further discloses methods of manufacturing and uses of the aforementioned composition.

Preparations of cannabis emulsions and methods thereof

The present disclosure provides cannabinoid-loaded formulations, as well as processes for their preparation

Dilutable formulations of cannabinoids and processes for their preparation

The present disclosurerelates to the use of cannabidiol (CBD) in the treatment of absence seizures. In particular, the disclosure relates to the use of CBD for reducing absence seizures in patients suffering withetiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; CDKL5; Dup15q;, Jeavons syndrome; Myoclonic Absence Epilepsy;Neuronal ceroid lipofuscinoses(NCL) and brain abnormalities. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Use of cannabidiol in the treatment of epilepsy

The invention relates to the field of pharmaceutic preparations and in particular relates to micro-emulsion containing a cannabinol compound. The micro-emulsion comprises the following components in percentage by weight: (a), 0.01wt%-30wt% of the cannabinol compound; (b), 0.01wt%-30wt% of oil phase, wherein the oil phase is selected from one or more of vegetable oil, fatty acid ethyl ester, fatty acid isopropyl ester, fatty acid glyceride and fatty acid polyethylene glycol glyceride; (c), 0.01wt%-60wt% of surfactant, wherein the surfactant is selected from one or more of polyoxyethylene ether castor oil, polyoxyethylene hydrogenated castor oil, poloxamer, fatty acid polyethylene glycol glyceride, polyoxyethylene dehrdrated sorbitol aliphatic ester and phospholipid; (d), 0.01wt%-40wt% of cosurfactant, wherein the cosurfactant is selected from one or more of alcohol, propylene glycol, isopropyl alcohol, polyethylene glycol, dimethyl isosorbide, isopropenyl carbonate, diethylene glycol monoethyl ether, tetrahydrofuran polyglycol ether and glycerol; and the balance being water or deionized water.

Cannabinol compound micro-emulsion and preparation method thereof

The invention relates to the pharmaceutical field, and especially relates to medical applications of flavonol derivatives with the structural formula (I), wherein R1 and R2 are selected from hydroxyl or 2,6-dimethyl-6-hydroxyl-2,7-octadiene acyl independently; R3 is selected from hydrogen or methoxyl; R4 is selected from hydroxyl or XCH2(CHOH)4CO-, when R4 is XCH2(CHOH)4CO-, X is selected from hydroxyl or erucic acyl. The flavonol derivatives with the structural formula (I), or pharmaceutically acceptable salts, hydrates or prodrug thereof can be used for treating hyperlipemia.

Lv Feng

Papers

Cannabinol compound micro-emulsion and preparation method thereof

Medical applications of flavonol derivatives